

**Emergence and evolution of *TP53* mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide**

Laurence Lodé,<sup>1,2,3,4</sup> Audrey Ménard,<sup>2</sup> Laurent Flet,<sup>5</sup> Steven Richebourg,<sup>6</sup> Marion Loirat,<sup>7</sup> Marion Eveillard,<sup>2</sup> Yannick Le Bris,<sup>2</sup> Catherine Godon,<sup>2</sup> Olivier Theisen,<sup>2</sup> Anne-Laure Gagez,<sup>8</sup> Guillaume Cartron,<sup>3,8</sup> Thérèse Commes-Maerten,<sup>4</sup> Bruno Villemagne,<sup>9</sup> Odile Luyckx,<sup>10</sup> Pascal Godmer,<sup>11</sup> Catherine Pellat-Deceunynck,<sup>12</sup> Thierry Soussi,<sup>13</sup> Marie C. Béné,<sup>2</sup> Jacques Delaunay<sup>7,14</sup> and Pierre Peterlin<sup>7</sup>

<sup>1</sup>Hematology Biology, Montpellier University Hospital, France; <sup>2</sup>Hematology Biology, Nantes University Hospital, France; <sup>3</sup>UMR CNRS5235, University of Montpellier; <sup>4</sup>Bio2M team, Institut de Recherche en Médecine Régénératrice, INSERM U1183, Hôpital Saint-Eloi, Montpellier, France; <sup>5</sup>Pharmacy Unit, Nantes University Hospital, France; <sup>6</sup>Cytogenetics, Québec University Hospital, Hôpital Saint Sacrement, Québec, Canada; <sup>7</sup>Hematology Clinic, Nantes University Hospital, France; <sup>8</sup>Hematology Department, University Hospital, Montpellier, France; <sup>9</sup>Hematology Clinic, CH La Roche-sur-Yon, France; <sup>10</sup>Hematology Clinic, CH Lorient, France; <sup>11</sup>Hematology Clinic, CH Vannes, France; <sup>12</sup>CRCINA, INSERM, CNRS, Angers University, Nantes University, France; <sup>13</sup>Sorbonne Université, UPMC Univ Paris 06, France; INSERM, U1138, Centre de Recherche des Cordeliers, Paris, France; Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska (CCK), Stockholm, Sweden and <sup>14</sup>Hematology Department, Le Confluent, Nantes, France

JD and PP contributed equally to this work

Correspondence: [mariechene@gmail.com](mailto:mariechene@gmail.com)


doi:10.3324/haematol.2017.181404

**Supplemental Table 1. Patients details**

#	Age (y)	Sex	IPSSR	Karyotype	TP53 mut at diagnosis	TP53 mut At follow-up	Progression	Alive
1	70	F	3	46,XX,del(5)(q13q32)	No	Yes	AML	No
2	51	F	3.5	46,XX,del(5)(q21q35)	Yes	Yes	No	Yes
3	75	F	3.5	FISH del(5q)	No	No	No	No
4	77	F	3.5	46,XX,del(5)(q14q34)	No	Yes	MDS-EB I	Yes
5	61	F	2.5	46,XX,del(5)(q14q34)	No	No	No	Yes
6	73	M	3	46,XX,del(5)(q15q35)	No	Yes	No	Yes
7	77	F	3.5	46,XX,del(5)(q13q34)	No	Yes	MDS-EB II	No
8	74	F	2	46,XX,del(5)(q14q34)	No	No	No	No
9	73	F	1	46,XX,del(5)(q14q34)	No	No	No	Yes
10	71	M	2	46,XY,del(5)(q14q34)	No	Yes	MDS-EB II	No
11	79	F	2.5	46,XX,del(5)(q14q34)	Yes	Yes	No	Yes
12	61	F	4.5	47,XX,del(5)(q15q35), +8	Yes	Yes	MDS-EB II / AML	No
13	71	F	4.5	46,XX,del(5)(q14q34), +8	Yes	Yes	No	No
14	62	F	3	46,XX,del(5)(q13q35)	No	No	No	Yes
15	63	M	4	46,XY,del(5)(q14q34)	No	Yes	AML	No
16	64	F	2.5	46,XX,del(5)(q22q35)	No	No	No	No
17	76	F	3.5	46,XX,del(5)(q15q35), t(9;12)	No	No	AML	No
18	58	F	3	46,XX,del(5)(q14q34)	No	Yes	MDS-EB II	No
19	78	F	3	46,XX,del(5)(q13q24)	Yes	Yes	No	No
20	76	F	3	46,XX,del(5)(q12q31)	No	No	No	Yes
21	58	F	1	46,XX,del(5)(q14q35)	No	Yes	AML	Yes
22	55	M	2	46,XY,del(5)(q14q35), del(20)(q11q13)	Yes	Yes	AML	Yes
23	62	M	2	46,XY,del(5)(q21q35)	No	Yes	MDS-EB II / AML	No
24	75	F	1	46,XX,del(5)(q12q34)	No	No	No	No

1

Supplemental Figure 1. Evolution of the 11 patients for whom *TP53* appeared during therapy.



2

3